Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and Ipamorelin — mechanism, dosing, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) originally developed by Novo Nordisk and later advanced by Helsinn/Nycomed. It is a selective ghrelin receptor agonist / growth hormone secretagogue (GHRP). Its defining feature versus older GHRPs (GHRP-2, GHRP-6, hexarelin) is that in preclinical and early clinical studies it raised GH without meaningfully increasing ACTH, cortisol, or prolactin. It is not FDA-approved for any indication; a Phase 2 trial for postoperative ileus failed to meet its primary endpoint and clinical development was discontinued. In the wellness/grey market it is sold as a research chemical and used off-label for anti-aging and body-composition goals despite no clinically validated human dose for those uses.
BPC-157
Ipamorelin
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
Ipamorelin
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
334
COAs
99.3%
Avg purity
16
Labs
Ipamorelin
153
COAs
99.7%
Avg purity
17
Labs
BPC-157 and Ipamorelin are both among peptides under FDA review for the Category 1 (503A) list; if added, they would require a prescription to be compounded by registered 503A/503B pharmacies — they are not yet authorized. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
The seminal preclinical characterization (Raun et al., 1998, PMID 9849822) established ipamorelin as the first GHRP-receptor agonist with GH-release selectivity comparable to GHRH, without raising ACTH or cortisol even at doses more than 200-fold above the ED50. Pharmacokinetic-pharmacodynamic modeling in healthy male volunteers (Gobburu et al., 1999, PMID 10496658) confirmed a roughly 2-hour half-life and dose-dependent GH response following IV infusion. The most advanced human study is Beck et al. (2014, PMID 25331030), a Phase 2, randomized, double-blind, placebo-controlled trial in 114 patients after bowel resection evaluating IV ipamorelin 0.03 mg/kg twice daily for postoperative ileus; the drug was well tolerated but did not separate from placebo on the primary endpoint (time to tolerance of solid food), and the sponsor (Helsinn/Nycomed) discontinued development. There are no completed registrational trials in adult GH deficiency, frailty, or body-composition indications. Ipamorelin is not FDA-approved for any indication. The 100–300 mcg dose range reflects community/compounding practice and is not clinically validated for anti-aging or body-composition use.
BPC-157 (Recovery) and Ipamorelin (Performance) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
Cheapest verified BPC-157: live prices, vendors & COA data
The cheapest verified BPC-157 by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 16 labs across 338 COAs.
Cheapest verified Ipamorelin: live prices, vendors & COA data
The cheapest verified Ipamorelin by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 17 labs across 163 COAs.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs